Journal of Public Health Policy

, Volume 36, Issue 4, pp 384–389 | Cite as

Viewpoint: Counterfeit medicines and substandard medicines: Different problems requiring different solutions

  • Ellen 't HoenEmail author
  • Fernando Pascual


New interest in the ‘pandemic’ of falsified medicines has resulted in efforts to put in place a treaty on ‘medicines crime’. If the goal is to protect the interests of people and public health, an international agreement to ensure that all proven effective and necessary medicines are affordable, available, and of assured quality will do far more to combat falsified and substandard medicines than an agreement that deals primarily with the criminal aspects of problematic medicines production and distribution.


counterfeit medicines medicines quality access to medicines 


  1. Nayyar, G.M., Breman, J.G. and Herrington, J. (2015) The global pandemic of falsified medicines: Laboratory and field innovations and policy perspectives: Summary. The American Journal of Tropical Medicine and Hygiene, 92(6): 2–7., accessed 12 May 2015.
  2. Benkimoun, P. (2015) Alerte sur le fléau des mauvais medicaments. Le Monde,, accessed 10 June 2015.
  3. Ford, N. and ’t Hoen, E. (2002) Generic medicines are not substandard medicines. The Lancet, 359(9314), 1351;'t%20Hoen%202002.pdf, accessed 25 june 2015.
  4. International Medical Products Anti-Counterfeiting Taskforce. (2007) Draft principles and elements for national legislation against counterfeit medical products. Background document for a meeting of experts Lisbon, Portugal 10–11 December 2007,, accessed 10 June 2015.
  5. Attaran, A. (2015) Model law on medicine crime, 15 April, or, accessed 25 june 2015.
  6. World Health Organization. (2015) Essential medicines and health products: General information on counterfeit medicines,
  7. Caudron, J.M., Ford, N., Henkens, M., Mace, C., Kiddle‐Monroe, R. and Pinel, J. (2008) Substandard medicines in resource‐poor settings: A problem that can no longer be ignored. Tropical Medicine & International Health 13 (8): 1062–1072.CrossRefGoogle Scholar
  8. Stringent Drug Regulatory Authority (SRA):, accessed 10 june 2015.
  9. Access Campaign/MSF. (2014) Untangling the web of antiretroviral price reductions, 17th Edition, July,, accessed 10 June 2015.
  10. Waning, B., Diedrichsen, E. and Moon, S. (2010) A lifeline to treatment: The role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. Journal of the International AIDS Society, 13(1), 35,, accessed 13 May 2015.
  11. ‘t Hoen, E.F.M., Hogerzeil, H.V., Quick, J.D. and Sillo, H.B. (2014) A quiet revolution in global public health: The world health organization’s prequalification of medicines programme. Journal of Public Health Policy 35 (2): 137–161.CrossRefGoogle Scholar
  12. World Health Organization. (2015) Annex 1, 19th WHO model list of essential medicines, April,, accessed 10 June 2015.

Copyright information

© Palgrave Macmillan, a division of Macmillan Publishers Ltd 2015

Authors and Affiliations

  1. 1.Medicines Law and PolicyParisFrance
  2. 2.Quamed, Institute of Tropical MedicineAntwerpBelgium

Personalised recommendations